CoChat
Sign Up
Cited by 134Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease

Open access
Mhatre, Siddhita D., Tsai, Connie A., Rubin, Amanda J., James, Michelle L., Andreasson, Katrin I.·2015·Trends in Neurosciences
DOI 10.1016/j.tins.2015.08.006PMC PMC4670239
Open this paper in CoChat — free account

Abstract

Studies of Alzheimer's disease (AD) have predominantly focused on two major pathologies: amyloid-β (Aβ) and hyperphosphorylated tau. These misfolded proteins can accumulate asymptomatically in distinct regions over decades. However, significant Aβ accumulation can be seen in individuals who do not develop dementia, and tau pathology limited to the transentorhinal cortex, which can appear early in adulthood, is usually clinically silent. Thus, an interaction between these pathologies appears to be necessary to initiate and propel disease forward to widespread circuits. Recent multidisciplinary findings strongly suggest that the third factor required for disease progression is an aberrant microglial immune response. This response may initially be beneficial; however, a maladaptive microglial response eventually develops, fueling a feed-forward spread of tau and Aβ pathology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tins.2015.08.006

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 97

  1. Aubry S Shin W Crary JF Lefort R Qureshi YH Lefebvre C Shelanski ML 2015 Assembly and interrogation of Alzheimer’s disease genetic networks reveal novel regulators of progression PLoS One 10 e0120352 25781952 PMC4363671
  2. Augustin R Lichtenthaler SF Greeff M Hansen J Wurst W Trumbach D 2011 Bioinformatics identification of modules of transcription factor binding sites in Alzheimer’s disease-related genes by in silico promoter analysis and microarrays International journal of Alzheimer’s disease 2011 154325 PMC3090009 21559189
  3. Batarseh A Papadopoulos V 2010 Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states Molecular and cellular endocrinology 327 1 12 20600583 PMC2922062
  4. Berti V Pupi A Mosconi L 2011 PET/CT in diagnosis of dementia Ann N Y Acad Sci 1228 81 92 21718326 PMC3692287
  5. Biffi A Shulman JM Jagiella JM Cortellini L Ayres AM Schwab K Rosand J 2012 Genetic variation at CR1 increases risk of cerebral amyloid angiopathy Neurology 78 334 341 22262751 PMC3280047
  6. Braak H Braak E 1995 Staging of Alzheimer’s disease-related neurofibrillary changes Neurobiol Aging 16 271 278 discussion 278–284 7566337
  7. Braak H Thal DR Ghebremedhin E Del Tredici K 2011 Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years J Neuropathol Exp Neurol 70 960 969 22002422
  8. Bradt BM Kolb WP Cooper NR 1998 Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide J Exp Med 188 431 438 9687521 PMC2212467
  9. Bralten J Franke B Arias-Vasquez A Heister A Brunner HG Fernandez G Rijpkema M 2011 CR1 genotype is associated with entorhinal cortex volume in young healthy adults Neurobiol Aging 32 2106 e2107 2111 21726919
  10. Cagnin A Brooks DJ Kennedy AM Gunn RN Myers R Turkheimer FE Banati RB 2001 In-vivo measurement of activated microglia in dementia Lancet 358 461 467 11513911
  11. Carrasquillo MM Crook JE Pedraza O Thomas CS Pankratz VS Allen M Ertekin-Taner N 2015 Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease Neurobiol Aging 36 60 67 25189118 PMC4268433
  12. Chauveau F Boutin H Van Camp N Dolle F Tavitian B 2008 Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers European journal of nuclear medicine and molecular imaging 35 2304 2319 18828015
  13. Chen MK Guilarte TR 2008 Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair Pharmacology & therapeutics 118 1 17 18374421 PMC2453598
  14. Chibnik LB Shulman JM Leurgans SE Schneider JA Wilson RS Tran D De Jager PL 2011 CR1 is associated with amyloid plaque burden and age-related cognitive decline Ann Neurol 69 560 569 21391232 PMC3066288
  15. Chibnik LB Yu L Eaton ML Srivastava G Schneider JA Kellis M De Jager PL 2015 Alzheimer’s loci: epigenetic associations and interaction with genetic factors Annals of Clinical and Translational Neurology PMC4479524 26125039
  16. Ching AS Kuhnast B Damont A Roeda D Tavitian B Dolle F 2012 Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases Insights into imaging 3 111 119 22696004 PMC3292648
  17. Cole GM Ard MD 2000 Influence of lipoproteins on microglial degradation of Alzheimer’s amyloid beta-protein Microscopy research and technique 50 316 324 10936886
  18. Cruchaga C Kauwe JS Harari O Jin SC Cai Y Karch CM Goate AM 2013 GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer’s disease Neuron 78 256 268 23562540 PMC3664945
  19. Cudaback E Li X Montine KS Montine TJ Keene CD 2011 Apolipoprotein E isoform-dependent microglia migration FASEB J 25 2082 2091 21385991 PMC3101033
  20. Cudaback E Yang Y Montine TJ Keene CD 2015 APOE genotype-dependent modulation of astrocyte chemokine CCL3 production Glia 63 51 65 25092803 PMC4237722
  21. DeMattos RB O’Dell M A Parsadanian M Taylor JW Harmony JA Bales KR Holtzman DM 2002 Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease Proc Natl Acad Sci U S A 99 10843 10848 12145324 PMC125060
  22. Desikan RS Thompson WK Holland D Hess CP Brewer JB Zetterberg H Alzheimer’s Disease Neuroimaging Initiative, G 2014 The role of clusterin in amyloid-beta-associated neurodegeneration JAMA neurology 71 180 187 24378367 PMC4118752
  23. Eon Kuek L Leffler M Mackay GA Hulett MD 2015 The MS4A family: counting past 1, 2 and 3 Immunology and cell biology 25835430
  24. Frasca D Blomberg BB 2015 Inflammaging decreases adaptive and innate immune responses in mice and humans Biogerontology PMC4626429 25921609
  25. Fuhrmann M Bittner T Jung CK Burgold S Page RM Mitteregger G Herms J 2010 Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer’s disease Nat Neurosci 13 411 413 20305648 PMC4072212
  26. Funk CD FitzGerald GA 2007 COX-2 inhibitors and cardiovascular risk J Cardiovasc Pharmacol 50 470 479 18030055
  27. Gjoneska E Pfenning AR Mathys H Quon G Kundaje A Tsai LH Kellis M 2015 Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease Nature 518 365 369 25693568 PMC4530583
  28. Golla SS Boellaard R Oikonen V Hoffmann A van Berckel BN Windhorst AD Rinne JO 2015 Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer’s disease patients J Cereb Blood Flow Metab 35 766 772 25649991 PMC4420859
  29. Gosselin D Link VM Romanoski CE Fonseca GJ Eichenfield DZ Spann NJ Glass CK 2014 Environment drives selection and function of enhancers controlling tissue-specific macrophage identities Cell 159 1327 1340 25480297 PMC4364385
  30. Griciuc A Serrano-Pozo A Parrado AR Lesinski AN Asselin CN Mullin K Tanzi RE 2013 Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta Neuron 78 631 643 23623698 PMC3706457
  31. Guerreiro R Wojtas A Bras J Carrasquillo M Rogaeva E Majounie E Alzheimer Genetic Analysis, G 2013 TREM2 variants in Alzheimer’s disease N Engl J Med 368 117 127 23150934 PMC3631573
  32. Guo Y Kalathur RC Liu Q Kloss B Bruni R Ginter C Hendrickson WA 2015 Protein structure. Structure and activity of tryptophan-rich TSPO proteins Science 347 551 555 25635100 PMC4341906
  33. Han J Jiang Y Li Z Kravchenko VV Ulevitch RJ 1997 Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation Nature 386 296 299 9069290
  34. Hardy JA Higgins GA 1992 Alzheimer’s disease: the amyloid cascade hypothesis Science 256 184 185 1566067
  35. Harms AS Cao S Rowse AL Thome AD Li X Mangieri LR Standaert DG 2013 MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration J Neurosci 33 9592 9600 23739956 PMC3903980
  36. Hebert LE Scherr PA Bienias JL Bennett DA Evans DA 2003 Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch Neurol 60 1119 1122 12925369
  37. Hollingworth P Harold D Sims R Gerrish A Lambert JC Carrasquillo MM Williams J 2011 Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease Nature genetics 43 429 435 21460840 PMC3084173
  38. Jacobs AH Tavitian B 2012 Noninvasive molecular imaging of neuroinflammation J Cereb Blood Flow Metab 32 1393 1415 22549622 PMC3390799
  39. Jehle AW Gardai SJ Li S Linsel-Nitschke P Morimoto K Janssen WJ Tall AR 2006 ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages The Journal of cell biology 174 547 556 16908670 PMC2064260
  40. Jiang T Yu JT Hu N Tan MS Zhu XC Tan L 2014 CD33 in Alzheimer’s disease Molecular neurobiology 49 529 535 23982747
  41. Johnson ME Deliard S Zhu F Xia Q Wells AD Hankenson KD Grant SF 2014 A ChIP-seq-defined genome-wide map of MEF2C binding reveals inflammatory pathways associated with its role in bone density determination Calcified tissue international 94 396 402 24337390
  42. Karch CM Jeng AT Nowotny P Cady J Cruchaga C Goate AM 2012 Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains PLoS One 7 e50976 23226438 PMC3511432
  43. Kim WS Fitzgerald ML Kang K Okuhira K Bell SA Manning JJ Freeman MW 2005 Abca7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels J Biol Chem 280 3989 3995 15550377
  44. Kim WS Guillemin GJ Glaros EN Lim CK Garner B 2006 Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells Neuroreport 17 891 896 16738483
  45. Kim WS Li H Ruberu K Chan S Elliott DA Low JK Garner B 2013 Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer’s disease J Neurosci 33 4387 4394 23467355 PMC6704948
  46. Kitazawa M Oddo S Yamasaki TR Green KN LaFerla FM 2005 Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease J Neurosci 25 8843 8853 16192374 PMC6725603
  47. Koslowski M Sahin U Dhaene K Huber C Tureci O 2008 MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes Cancer Res 68 3458 3466 18451174
  48. Kreisl WC Lyoo CH McGwier M Snow J Jenko KJ Kimura N Innis RB 2013 In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease Brain 136 2228 2238 23775979 PMC3692038
  49. Lancaster TM Brindley LM Tansey KE Sims RC Mantripragada K Owen MJ Linden DE 2014 Alzheimer’s disease risk variant in CLU is associated with neural inefficiency in healthy individuals Alzheimers Dement 25496871
  50. Lavin Y Winter D Blecher-Gonen R David E Keren-Shaul H Merad M Amit I 2014 Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment Cell 159 1312 1326 25480296 PMC4437213
  51. Lee DC Rizer J Selenica ML Reid P Kraft C Johnson A Morgan D 2010a LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice J Neuroinflammation 7 56 20846376 PMC2949628
  52. Li F Liu J Zheng Y Garavito RM Ferguson-Miller S 2015a Protein structure. Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism Science 347 555 558 25635101 PMC5125025
  53. Li Y Liu L Barger SW Griffin WS 2003 Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway J Neurosci 23 1605 1611 12629164 PMC3833596
  54. Liang X Lin L Wang Q Woodling NS Anacker C Pan T Merchant M Andreasson K 2011 Neuronal and vascular protection by the prostaglandin E2 EP4 receptor in a mouse model of cerebral ischemia J Clin Invest 121 4362 4371 21965326 PMC3204834
  55. Lidstrom AM Bogdanovic N Hesse C Volkman I Davidsson P Blennow K 1998 Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease Exp Neurol 154 511 521 9878186
  56. Luo J Li S Qin X Song L Peng Q Chen S Zeng Z 2014 Meta-analysis of the association between CR1 polymorphisms and risk of late-onset Alzheimer’s disease Neurosci Lett 578 165 170 24996192
  57. Maezawa I Nivison M Montine KS Maeda N Montine TJ 2006a Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK FASEB J 20 797 799 16481366
  58. Maezawa I Zaja-Milatovic S Milatovic D Stephen C Sokal I Maeda N Montine KS 2006b Apolipoprotein E isoform-dependent dendritic recovery of hippocampal neurons following activation of innate immunity J Neuroinflammation 3 21 16934151 PMC1584222
  59. Malik M Simpson JF Parikh I Wilfred BR Fardo DW Nelson PT Estus S 2013 CD33 Alzheimer’s risk-altering polymorphism, CD33 expression, and exon 2 splicing J Neurosci 33 13320 13325 23946390 PMC3742922
  60. Maze I Shen L Zhang B Garcia BA Shao N Mitchell A Nestler EJ 2014 Analytical tools and current challenges in the modern era of neuroepigenomics Nat Neurosci 17 1476 1490 25349914 PMC4262187
  61. Melchior B Garcia AE Hsiung BK Lo KM Doose JM Thrash JC Carson MJ 2010 Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer’s disease ASN neuro 2 e00037 20640189 PMC2905103
  62. Miller JA Woltjer RL Goodenbour JM Horvath S Geschwind DH 2013 Genes and pathways underlying regional and cell type changes in Alzheimer’s disease Genome medicine 5 48 23705665 PMC3706780
  63. Mulder SD Nielsen HM Blankenstein MA Eikelenboom P Veerhuis R 2014 Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro Glia 62 493 503 24446231
  64. Parkhurst CN Yang G Ninan I Savas JN Yates JR 3rd Lafaille JJ Gan WB 2013 Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor Cell 155 1596 1609 24360280 PMC4033691
  65. Peng Q Malhotra S Torchia JA Kerr WG Coggeshall KM Humphrey MB 2010 TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1 Science signaling 3 ra38 20484116 PMC2900152
  66. Proitsi P Lee SH Lunnon K Keohane A Powell J Troakes C AddNeuroMed, C 2014 Alzheimer’s disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood Neurobiol Aging 35 279 290 24064185
  67. Replogle JM Chan G White CC Raj T Winn PA Evans DA De Jager PL 2015 A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology Ann Neurol 77 469 477 25545807 PMC4461024
  68. Sakamoto A Sugamoto Y Tokunaga Y Yoshimuta T Hayashi K Konno T Yamagishi M 2011 Expression profiling of the ephrin (EFN) and Eph receptor (EPH) family of genes in atherosclerosis-related human cells The Journal of international medical research 39 522 527 21672356
  69. Schenk M Bouchon A Seibold F Mueller C 2007 TREM-1–expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases J Clin Invest 117 3097 3106 17853946 PMC1974863
  70. Schrijvers EM Koudstaal PJ Hofman A Breteler MM 2011 Plasma clusterin and the risk of Alzheimer disease Jama 305 1322 1326 21467285
  71. Schuitemaker A Kropholler MA Boellaard R van der Flier WM Kloet RW van der Doef TF van Berckel BN 2013 Microglial activation in Alzheimer’s disease: an (R)-[(1)(1)C]PK11195 positron emission tomography study Neurobiol Aging 34 128 136 22840559
  72. Shen Y Lue L Yang L Roher A Kuo Y Strohmeyer R Rogers J 2001 Complement activation by neurofibrillary tangles in Alzheimer’s disease Neurosci Lett 305 165 168 11403931
  73. Shi J Johansson J Woodling NS Wang Q Montine TJ Andreasson K 2010 The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity J Immunol 184 7207 7218 20483760 PMC3103215
  74. Shulman JM Chen K Keenan BT Chibnik LB Fleisher A Thiyyagura P Bennett DA 2013 Genetic susceptibility for Alzheimer disease neuritic plaque pathology JAMA neurology 70 1150 1157 23836404 PMC3773291
  75. Sperling R Mormino E Johnson K 2014 The evolution of preclinical Alzheimer’s disease: implications for prevention trials Neuron 84 608 622 25442939 PMC4285623
  76. Streit WJ Braak H Xue QS Bechmann I 2009 Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease Acta Neuropathol 118 475 485 19513731 PMC2737117
  77. Suridjan I Pollock BG Verhoeff NP Voineskos AN Chow T Rusjan PM Mizrahi R 2015 In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand, [F]-FEPPA Mol Psychiatry PMC8026116 25707397
  78. Takeshita S Namba N Zhao JJ Jiang Y Genant HK Silva MJ Ross FP 2002 SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts Nat Med 8 943 949 12161749
  79. Thal DR Rub U Orantes M Braak H 2002 Phases of A beta-deposition in the human brain and its relevance for the development of AD Neurology 58 1791 1800 12084879
  80. Viernes DR Choi LB Kerr WG Chisholm JD 2014 Discovery and development of small molecule SHIP phosphatase modulators Medicinal research reviews 34 795 824 24302498 PMC4991215
  81. Vitek MP Brown CM Colton CA 2009 APOE genotype-specific differences in the innate immune response Neurobiol Aging 30 1350 1360 18155324 PMC2782461
  82. Vlad SC Miller DR Kowall NW Felson DT 2008 Protective effects of NSAIDs on the development of Alzheimer disease Neurology 70 1672 1677 18458226 PMC2758242
  83. Wake H Moorhouse AJ Miyamoto A Nabekura J 2013 Microglia: actively surveying and shaping neuronal circuit structure and function Trends Neurosci 36 209 217 23260014
  84. Wang HF Tan L Hao XK Jiang T Tan MS Liu Y Alzheimer’s Disease Neuroimaging, I 2015a Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts J Alzheimers Dis 44 115 123 25182741
  85. Wang Y Cella M Mallinson K Ulrich JD Young KL Robinette ML Colonna M 2015b TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model Cell 160 1061 1071 25728668 PMC4477963
  86. Weber B Schuster S Zysset D Rihs S Dickgreber N Schurch C Mueller C 2014 TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance PLoS pathogens 10 e1003900 24453980 PMC3894224
  87. Wes PD Easton A Corradi J Barten DM Devidze N DeCarr LB Cacace AM 2014 Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer’s disease PLoS One 9 e106050 25153994 PMC4143352
  88. Wiley CA Lopresti BJ Venneti S Price J Klunk WE DeKosky ST Mathis CA 2009 Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease Arch Neurol 66 60 67 19139300 PMC2666881
  89. Woodling NS Wang Q Priyam PG Larkin P Shi J Johansson JU Andreasson KI 2014 Suppression of Alzheimer-Associated Inflammation by Microglial Prostaglandin-E2 EP4 Receptor Signaling J Neurosci 34 5882 5894 24760848 PMC3996215
  90. Xu Q Li Y Cyras C Sanan DA Cordell B 2000 Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle J Biol Chem 275 31770 31777 10918055
  91. Xue J Schmidt SV Sander J Draffehn A Krebs W Quester I Schultze JL 2014 Transcriptome-based network analysis reveals a spectrum model of human macrophage activation Immunity 40 274 288 24530056 PMC3991396
  92. Yasuno F Ota M Kosaka J Ito H Higuchi M Doronbekov TK Suhara T 2008 Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106 Biol Psychiatry 64 835 841 18514164
  93. Yu L Chibnik LB Srivastava GP Pochet N Yang J Xu J Bennett DA 2015 Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease JAMA neurology 72 15 24 25365775 PMC4344367
  94. Zhang B Gaiteri C Bodea LG Wang Z McElwee J Podtelezhnikov AA Emilsson V 2013 Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease Cell 153 707 720 23622250 PMC3677161
  95. Zhang J Somani AK Siminovitch KA 2000 Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling Seminars in immunology 12 361 378 10995583
  96. Zhao QF Yu JT Tan MS Tan L 2014 ABCA7 in Alzheimer’s Disease Molecular neurobiology 24878767
  97. Zilka N Stozicka Z Kovac A Pilipcinec E Bugos O Novak M 2009 Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy J Neuroimmunol 209 16 25 19232747

Cited by

Sorted by citations

Authors
Mhatre, S. D., Tsai, C. A., Rubin, A. J., James, M. L., & Andreasson, K. I.
Affiliations
Stanford Medicine (US)
Corresponding author
Andreasson, Katrin I.
ORCID
Venue
Trends in Neurosciences
Publisher
Elsevier BV
Published
2015-10
Volume
38
Issue
10
Pages
621-636
ISSN
0166-2236 (ISSN-L)
DOI
10.1016/j.tins.2015.08.006
PMC
PMC4670239
OpenAlex
W2107986249
Cited by
134
References
38
Citations by year
2026: 5 · 2025: 7 · 2024: 5 · 2023: 14 · 2022: 12 · 2021: 13 · 2020: 21 · 2019: 13 · 2018: 11 · 2017: 17 · 2016: 15 · 2015: 1
FWCI
1.17
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Trends in Neurosciences (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (AG15799, R01AG030209, R21AG033914, R01AG015799, AG030209, AG033914)
  • National Institute of Mental Health (T32MH020016)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, microglia, microglial dysfunction, amyloid-beta, tau pathology, neuroinflammation, disease progression, transentorhinal cortex, neurodegeneration
MeSH terms
Alzheimer Disease, Animals, Brain, Humans, Microglia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review